# Curegene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curegene

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.curegene.com.cn
- Total disclosed funding: $58M
- Latest round: Series C (May 12, 2026)
- Investors on record: 15

## About

Founded in 2018 and based in Shanghai, China, Shanghai CureGene Pharmaceutical Co,.Ltd, trading as Curegene, is a pharmaceutical technology company that provides small molecule and nucleic acid drugs. Gongxin He, the company’s founder and CEO, served as a scientist and senior director of R&D at Gilead Sciences. In 2020, the company completed the construction of its prodrug technology platform. In 2022, it completed CG-0255 preclinical studies and IND filing preparations.  In May 2026, Curegene raised over CNY 300 million in series C funding led by Walvax, with participation from Qianhai Ark Capital, Zhongxiaodan Venture Capital, Taikun Fund, and other investors.

The company has built the targeted prodrug and nucleic acid drug technology platform, and is committed to the research and development of small molecules and nucleic acid drugs for the treatment of cardiovascular and cerebrovascular diseases and antiviral. The company's new antiplatelet drug CG-0255 is a P2Y12 receptor antagonist. The drug has completed Phase I clinical trials in the United States, including injection and oral preparations, and can be used for antiplatelet treatment of cardiovascular and cerebrovascular diseases. Curegene has also developed a series of antiviral pipeline products such as CG-0980, CG-0985, and CG2021V, including drugs for children's RSV infection, functional cure of chronic hepatitis B, etc.

The company generates revenue by offering drugs in the treatment of cardiovascular and cerebrovascular diseases and antiviral.

The series C funds raised will be primarily used to accelerate the global clinical development of multiple core and key pipelines.

## Funding rounds

- Series C, May 12, 2026, $44M — Walvax, Qianhai Ark Capital, Zhongxiaodan Venture Capital, Taikun Fund
- Series B, May 20, 2025 — Guangdong Technology Financial Group
- Series B, Oct 31, 2024 — Infinity Group, Aeonmed, Qingdao Guoxin Venture, Honghai Chuangjian
- Series B, Jan 31, 2024, $14M — Hankang Capital, TigerYeah Capital, Taikun Fund, Elikon Venture, Honghai Chuangjian
- Series A, Jul 1, 2021 — Yonghua Capital, Zhejiang Ausun Pharmaceutical Co., Ltd, Shanghai Nanometer Venture Investment, Hankang Capital

## Investors

- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Zhejiang Ausun Pharmaceutical Co., Ltd — Series A
- Shanghai Nanometer Venture Investment (https://capitalatlas.ai/funds/shanghai-nanometer-venture-investment) — Series A
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series A, Series B
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series B
- Taikun Fund — Series B, Series C
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series B
- Honghai Chuangjian — Series B
- Infinity Group (https://capitalatlas.ai/funds/infinity-group) — Series B
- Aeonmed — Series B
- Qingdao Guoxin Venture — Series B
- Guangdong Technology Financial Group (https://capitalatlas.ai/funds/guangdong-technology-financial-group) — Series B
- Walvax — Series C
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series C
- Zhongxiaodan Venture Capital (https://capitalatlas.ai/funds/zhongxiaodan-venture-capital) — Series C